Stockscreener 앱 받기
29.49
2.16%
-0.65
시간 외 거래:
30.07
0.58
+1.97%
전일 마감가:
$30.14
열려 있는:
$30.28
하루 거래량:
1.19M
Relative Volume:
0.50
시가총액:
$3.76B
수익:
$-665.00K
순이익/손실:
$-150.11M
주가수익비율:
-19.57
EPS:
-1.5071
순현금흐름:
$-124.53M
1주 성능:
-9.01%
1개월 성능:
-21.28%
6개월 성능:
+113.23%
1년 성능:
+113.39%
1일 변동 폭
$29.47
$30.70
1주일 범위
$29.47
$33.19
52주 변동 폭
$10.83
$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-682-0917
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, TEVA, HLN, ZTS, VTRS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
29.49 | 3.76B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-03 | 개시 | Stifel | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - sg.finance.yahoo.com
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum - BioSpace
Amylyx Pharmaceuticals Stock Price Forecast. Should You Buy AMLX? - StockInvest.us
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Tapping into a 24.82% Upside Potential - DirectorsTalk Interviews
Amylyx Pharmaceuticals (AMLX) Signs Avexitide Supply Deals, Is The Stock Fully Priced? - simplywall.st
Amylyx (AMLX) Rallies +3.86% as Bulls Target $35.58 2026-09-17Sell Signal Alerts - careplusvn.com
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - webull.com
AMLX: Avexitide achieved strong efficacy in PBH, with NDA filing and launch preparations underway - TradingView
AMLX: Avexitide achieved robust efficacy in PBH, with NDA filing and commercial launch targeted for 2027 - tradingview.com
Amylyx (AMLX) CMO auto-sells 10,028 shares for taxes - stocktitan.net
Automatic tax sale by Amylyx (NASDAQ: AMLX) CFO - Stock Titan
Amylyx (NASDAQ: AMLX) co-CEO sells shares to cover taxes - Stock Titan
Amylyx Pharmaceuticals (AMLX) co-CEO sells shares to cover tax bill - Stock Titan
Automatic tax-share sale by Amylyx (AMLX) legal chief - Stock Titan
Amylyx Pharmaceuticals Insiders Sold Shares Worth Over $1.9M - TradingView
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Amylyx Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Automatic stock sale for taxes ahead at Amylyx Pharmaceuticals (AMLX) - Stock Titan
Amylyx (NASDAQ: AMLX) insider schedules automatic 60K-share sale - Stock Titan
Amylyx (NASDAQ: AMLX) officer lines up tax-driven share sale - Stock Titan
Amylyx (AMLX) insider schedules automatic tax share sale - Stock Titan
Automatic Amylyx (AMLX) stock sale set to cover taxes - Stock Titan
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Amylyx Pharmaceuticals Inks Avexitide Supply Deals With Bachem and Polypeptide; $30 Million Upfront to Reserve Capacity - TradingView
Amylyx Pharmaceuticals | 8-K: Current report - Moomoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference - Business Wire
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? - finance.yahoo.com
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - sahmcapital.com
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Oracle Stock And Two Other Growth Names With Stronger Balance Sheet Appeal - sahmcapital.com
Rocket Lab Stock Leads 3 High Growth Picks With Fresh Earnings Upside - Sahm
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.69%
자본화:
|
볼륨(24시간):